Skip to main content
Full access
New Research
Published Online: 1 February 2012

Childhood Maltreatment Predicts Unfavorable Course of Illness and Treatment Outcome in Depression: A Meta-Analysis

This article has been corrected.
VIEW CORRECTION

Abstract

Objectives:

Evidence suggests that childhood maltreatment may negatively affect not only the lifetime risk of depression but also clinically relevant measures of depression, such as course of illness and treatment outcome. The authors conducted the first meta-analysis to examine the relationship between childhood maltreatment and these clinically relevant measures of depression.

Method:

The authors conducted searches in MEDLINE, PsycINFO, and Embase for articles examining the association of childhood maltreatment with course of illness (i.e., recurrence or persistence) and with treatment outcome in depression that appeared in the literature before December 31, 2010. Recurrence was defined in terms of number of depressive episodes. Persistence was defined in terms of duration of current depressive episode. Treatment outcome was defined in terms of either a response (a 50% reduction in depression severity rating from baseline) or remission (a decrease in depression severity below a predefined clinical significance level).

Results:

A meta-analysis of 16 epidemiological studies (23,544 participants) suggested that childhood maltreatment was associated with an elevated risk of developing recurrent and persistent depressive episodes (odds ratio=2.27, 95% confidence interval [CI]=1.80–2.87). A meta-analysis of 10 clinical trials (3,098 participants) revealed that childhood maltreatment was associated with lack of response or remission during treatment for depression (odds ratio=1.43, 95% CI=1.11–1.83). Meta-regression analyses suggested that the results were not significantly affected by publication bias, choice of outcome measure, inclusion of prevalence or incidence samples, study quality, age of the sample, or lifetime prevalence of depression.

Conclusions:

Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression.
Major depression is a common and impairing illness, often exhibiting a recurrent and progressive course. Depression ranks among the most common psychiatric disorders worldwide, with a 12-month prevalence between 10% and 17% and a lifetime prevalence between 17% and 40% (1, 2). Because the lifetime prevalence of depression is at most four times its 12-month prevalence, depressive episodes are not independent events uniformly distributed in the population but rather tend to cluster in the same individuals. Consistent with this evidence, 60% of individuals who have recovered from a depressive episode will have a recurrence within 5 years (3). The rate of recurrence may be even higher in individuals who experience more persistent depressive episodes and in those who have a poor treatment outcome with residual subthreshold symptoms (3, 4). Because of the large health impact and economic burden associated with a poor longitudinal course of depressive illness, it is important to identify factors that predict risk of developing recurrent and persistent depressive episodes and lack of remission or response during treatment for depression.
Childhood maltreatment may predict an unfavorable course of illness and treatment outcome. Compared with individuals who have not been maltreated, those with a history of childhood maltreatment are at greater risk of meeting criteria for a depressive episode at any point in life (5). Maltreated individuals are also at greater risk of enduring cognitive (6) and biological (7) vulnerabilities associated with heightened stress sensitivity (8), which might predispose them to an unfavorable course of illness and treatment outcome. For example, maltreated individuals tend to have elevated inflammation levels (7, 9), which have been associated with recurrent depressive episodes (10) and poor treatment response (11).
To test whether individuals with a history of childhood maltreatment are at elevated risk of an unfavorable depression course and treatment outcome, we performed meta-analyses of epidemiological studies investigating the association between childhood maltreatment and depression recurrence or persistence and of clinical trials investigating the association between childhood maltreatment and outcome of psychological, pharmacological, or combined treatment. We also explored the effects of various possible sources of artifact or bias on the results of the meta-analyses.

Method

Inclusion Criteria

We identified studies satisfying the following criteria: definition of childhood adversities consistent with childhood maltreatment (physical abuse, sexual abuse, neglect, or family conflict or violence); diagnosis of depressive disorder, ascertained either in population-based or in clinical samples; and evaluation of relevant depression measures (12). Depression recurrence was defined in terms of number of depressive episodes over the period of observation or as risk of a new depressive episode in individuals with prior history of depression. Depression persistence was defined as prolonged duration of uninterrupted illness, including dysthymia, over the period of observation. Treatment outcome was defined as a change in depression scores between the beginning and the end of treatment, either as a continuous measure (i.e., improvement, defined as percentage improvement on a depression rating scale) or as a categorical outcome (i.e., response, defined as a reduction of depression rating scale score by 50% or more; or remission, defined as a decrease of depressive symptoms below a predetermined clinical significance level).

Identification of Studies

We searched MEDLINE, PsycINFO, and Embase databases for articles describing the relationship between childhood maltreatment (search terms: child* maltreatment, child* abuse, child* neglect, early experience) and relevant depression measures (search terms: depress*, mood disorder, MDD, recurrence, persistence, chronic, duration, length, improvement, response, remission, treatment, psychotherapy, CBT, pharmacotherapy, antidepressant, SSRI) using human subjects, written in English, and published by December 31, 2010.

Data Extraction

Two authors independently extracted data from eligible articles. Inconsistencies were resolved in consensus meetings and confirmed with the authors of the primary studies when necessary.

Statistical Analysis

Extracted data were converted to odds ratio effect sizes (13) reflecting the probability of unfavorable outcomes, with odds ratios above 1 reflecting a greater likelihood of recurrence, persistence, or poor treatment outcome in individuals with a history of childhood maltreatment compared to those without. The meta-analysis of clinical trials examined the difference in outcome between depressed patients with a history of childhood maltreatment and those without in the same active treatment arm. Where only continuous outcomes were reported, the risk of unfavorable outcomes was derived using validated methods (14). Heterogeneity between studies was tested with Cochran's Q test (15). In the presence of a homogeneous distribution, we carried out meta-analyses using fixed-effects models weighting each study by a measure of sampling error, such as the inverse variance. If the dispersion of effect sizes was greater than expected from sampling error alone (i.e., heterogeneity), we carried out meta-analyses using random-effects models, which include both sampling and study-level errors. Fixed- and random-effects meta-analyses were performed using the meta and metan programs applied in the Stata software package (StataCorp, College Station, Tex.). Additional analyses explored the effects of various possible sources of artifact or bias on the results.
First, we assessed the presence of publication bias visually by funnel plot (16) and formally by its direct statistical analogue, Begg's adjusted-rank correlation test (17), using the metabias program applied in Stata. In the presence of significant rank correlation tests, we adopted a nonparametric trim-and-fill method (18) using the metatrim program applied in Stata.
Second, we assessed the sensitivity of meta-analysis results to different outcome measures through subgroup analyses.
Third, we assessed the sensitivity of the results to different sampling strategies through subgroup analyses. Studies in clinical (or prevalence) samples and those in population (or incidence) samples could lead to different results because of ascertainment bias (19). The potential ascertainment bias could not have affected the results of clinical trials, which were restricted to clinical samples.
Fourth, we assessed the impact of study quality on the meta-analysis results through meta-regression using the metareg program applied in Stata. The quality of epidemiological studies was assessed with the Newcastle-Ottawa Scale (20), which has been recommended by the Cochrane collaboration (21) and has been used in previous studies (22). The quality of clinical trials was assessed by an adapted version of the Jadad scale (23) based on randomization, consideration of dropouts, and blinding. Because the contrast of interest was between individuals with a history of maltreatment and those without in the same active treatment arm, we considered blinding to maltreatment status rather than to treatment allocation.
Fifth, we assessed the presence of age effects through meta-regression analyses. Age effects could have influenced the meta-analysis results in two ways. With regard to the epidemiological studies, it was possible that because maltreated individuals are younger at the onset of depression than individuals without a history of maltreatment (24), they could spend more time at risk of recurrence and show greater depression recurrence and persistence for this reason. It was not possible to extract information on age at illness onset from the studies examined. However, we reasoned that the relative contribution of earlier age at onset to the total time that maltreated individuals spend at risk decays as the age of the sample increases. Therefore, if age at onset explained the association between childhood maltreatment and depression recurrence and persistence, we should have observed a significant negative correlation between mean age of the samples and effect sizes. With regard to the clinical trials, previous research has suggested that individuals at different ages could have a different response to the same antidepressant treatment (25). Therefore, it was possible that the age of the sample could have explained between-study differences in the association between childhood maltreatment and treatment outcomes in depression.
Finally, we assessed the presence of recall bias through meta-regression analyses. Most of the studies we examined were based on retrospective recall of childhood maltreatment. The reliability of retrospective recall of childhood maltreatment may be limited in individuals with a lifetime history of depression (26, 27) because of biases in autobiographical memory (28, 29). Therefore, to the extent that lifetime history of depression was different between the studies, it was possible that recall bias could have explained between-study differences in the association between childhood maltreatment and depression course. Recall bias was not an issue for the meta-analysis of the clinical trials, because all participants were depressed at the time the assessment of maltreatment history was carried out.

Results

The study selection procedure is summarized in Figure 1.
FIGURE 1. Study Selection Procedure for a Meta-Analysis of the Association Between Childhood Maltreatment and Course of Illness and Treatment Outcome in Depression

Epidemiological Studies

The association between childhood maltreatment and poor longitudinal course of depressive disorder (i.e., recurrence or persistence) was tested in 16 studies with a total of 23,544 participants (Table 1) (7, 3044). We identified significant heterogeneity across studies (Q=46.1, df=15, p<0.001) and therefore performed an analysis using a random-effects model. A meta-analysis of these studies showed that compared to those without a history of childhood maltreatment, maltreated individuals were twice as likely to have an unfavorable longitudinal course of depression (odds ratio=2.27, 95% confidence interval [CI]=1.80–2.87) (Figure 2). We performed additional analyses to explore the effects of possible sources of artifact or bias on these results.
TABLE 1. Selected Characteristics of Epidemiological Studies Investigating the Association Between Childhood Maltreatment and Depression Course: Recurrence and Persistencea
Authors (Reference)Study NMean Age or Range (Years)% FemaleSample TypeDepression MeasureMaltreatment MeasureOutcome DefinitionLength of Observation (Years)Results
Kessler and Magee (30)1,0243350PopulationDIS, FHRDCOwn questionnaireRecurrence: new depressive episode(s) in individuals with history of depression16Family violence associated with greater recurrence (odds ratio=2.04, 95% CI=1.42–2.93)
Brown and Moran (31)40418–50100PopulationPSECECAPersistence: depressive episode lasting 12 months or more3Childhood adversity associated with greater persistence (odds ratio=4.02, 95% CI=1.59–10.15)
Brown et al. (32)12518–60100ClinicalPSECECAPersistence: nonrecovery from depression over 12 months2Childhood adversity associated with greater persistence (odds ratio=1.93, 95% CI=1.05–3.54)
Zlotnick et al. (33)37 100ClinicalSemi-structured interviewOwn questionnairePersistence: non-recovery (HAM-D <7 for 3 consecutive months after hospital discharge)1Childhood adversity not associated with persistence (odds ratio=2.29, 95% CI=0.49–10.61)
Kessler et al. (34)5,87715–5450PopulationCIDIOwn questionnairePersistence: risk of dysthymia40Childhood adversity associated with greater persistence (odds ratio=2.81, p<0.05)
Bernet and Stein (35)884250ClinicalSCIDCTQRecurrence: number of depressive episodes25Childhood trauma associated with greater recurrence (t=4.78, p<0.0005)
Hayden and Klein (36)8631.175.6ClinicalSCID, longitudinal interval follow-up evaluationEHEIPersistence: nonrecovery from dysthymic disorder (<8 consecutive weeks with minimal or no symptoms)5Physical abuse associated with greater persistence (smaller recovery: hazard ratio=0.83, 95% CI=0.60–1.15)
Wainwright and Surtees (37)3,35362.355.2PopulationStructured self-assessmentOwn questionnaireRecurrence: number of depressive episodes46Physical abuse not associated with greater recurrence (relative risk=1.27; 95% CI=0.77–1.99)
Brown et al. (38)19834100PopulationSCANCECAPersistence: depressive episode lasting ≥12 months17Childhood adversity associated with greater recurrence (odds ratio=14.9, 95% CI=6.0–37.0)
Collishaw et al. (39)3,62444.250PopulationSADS-LCECARecurrence: ≥3 lifetime depressive episodes28Childhood adversity associated with greater recurrence (odds ratio=7.80, 95% CI=1.7–35.5)
Danese et al. (7)1,0373248PopulationDISProspective observation + retrospective reportsRecurrence: ≥2 lifetime depressive episodes21Childhood adversity associated with greater recurrence (odds ratio=2.60, 95% CI=1.60–4.24)
Ritchie et al. (40)9427258PopulationMINI diagnosis or CES-D >16 or current antidepressant treatmentOwn questionnaireRecurrence: ≥2 depressive episodes4Childhood adversity associated with greater recurrence (odds ratio=2.89, 95% CI=1.83–4.57)
Wiersma et al. (41)1,23040.767.3ClinicalCIDICTIPersistence: depressive episode lasting ≥24 months4Physical abuse associated with greater persistence (odds ratio=1.99, 95% CI=1.37–2.88)
Angst et al. (42)11027–4160ClinicalSPIKEOwn questionnairePersistence: depressive symptoms for most days over 2 years or daily for 12 months13Childhood adversity associated with greater persistence (p=0.05)
McLaughlin et al. (43)5,69236.742PopulationCIDIOwn questionnairePersistence: time since more recent episode, controlling for age at onset and time since onset20Physical abuse associated with greater persistence (odds ratio=1.9, 95% CI=1.5–2.4)
Suija et al. (44)1233985ClinicalCIDICTIRecurrence: new depressive episode in individuals with history of depression1Childhood trauma associated with greater recurrence (odds ratio=1.58, 95% CI=1.05–2.38)
a
CECA=Childhood Experience of Care and Abuse; CES-D=Center of Epidemiological Studies Depression Scale; CIDI=Composite International Diagnostic Interview; CTI=Childhood Trauma Interview; CTQ=Childhood Trauma Questionnaire; DIS=Diagnostic Interview Schedule; EHEI=Early Home Environment Interview; FHRDC=Family History Research Diagnostic Criteria; HAM-D=Hamilton Depression Rating Scale; MINI=Mini-International Neuropsychiatric Interview; PSE=Present State Examination; SADS-L=Schedule for Affective Disorders and Schizophrenia–Lifetime; SCAN=Schedule of Clinical Assessment in Neuropsychiatry; SCID=Structured Clinical Interview for DSM-IV; SPIKE=Structured Psychopathological Interview and Rating of the Social Consequences of Psychic Disturbances for Epidemiology.
FIGURE 2. Meta-Analysis of Epidemiological Studies Investigating the Association Between Childhood Maltreatment and Depression Course (Random Effects)a
a The red diamonds show the combined effect sizes for studies concerned with depression recurrence and depression persistence as well as the overall effect size of the meta-analysis (top to bottom).

Publication bias.

The funnel plot showed asymmetrical distribution of the studies, and results of Begg's adjusted-rank correlation test were significant (p=0.027), suggesting the possibility of publication bias. However, the trim-and-fill procedure achieved a similar combined effect size (odds ratio=1.78, 95% CI=1.38–2.31) to the nonfilled analysis, suggesting that potential publication bias did not significantly affect the results.

Sensitivity analyses.

First, we performed sensitivity analyses to examine whether the association between childhood maltreatment and course of illness was comparable across different measures of depression course (Figure 2). The association between childhood maltreatment and depression recurrence was tested in seven studies. We identified significant heterogeneity across studies (Q=15.1, df=6, p=0.020) and therefore performed an analysis using a random-effects model. A meta-analysis of these studies showed that maltreated individuals were twice as likely as those without a history of childhood maltreatment to develop recurrent depressive episodes (odds ratio=2.24, 95% CI=1.62–3.10). The association between childhood maltreatment and depression persistence was tested in nine studies. We identified significant heterogeneity across the studies (Q=30.60, df=8, p<0.001) and therefore performed an analysis using a random-effects model. A meta-analysis of these studies showed that maltreated individuals were twice as likely as those without a history of childhood maltreatment to develop persistent depressive episodes (odds ratio=2.34, 95% CI=1.65–3.32).
Second, we performed sensitivity analyses to examine whether the association between childhood maltreatment and course of illness was comparable across clinical and population samples. The association between childhood maltreatment and depression course was tested in seven clinical (prevalence) samples. Heterogeneity approached significance across studies (Q=10.69, df=6, p=0.098), so we performed an analysis using a random-effects model. A meta-analysis of the studies with clinical samples showed that maltreated individuals were nearly twice as likely as those without a history of childhood maltreatment to develop recurrent or persistant depressive episodes (odds ratio=1.78, 95% CI=1.36–2.34). The association between childhood maltreatment and depression course was tested in nine population (incidence) samples. We identified significant heterogeneity across the studies (Q=30.12, df=8, p<0.001) and therefore performed an analysis using a random-effects model. A meta-analysis of the studies with population samples showed that maltreated individuals were more than twice as likely as those without a history of childhood maltreatment to develop recurrent or persistent depressive episodes (odds ratio=2.75, 95% CI=1.94–3.91).

Bias owing to study quality.

Meta-regression analysis showed that between-study differences in quality ratings based on the Newcastle-Ottawa Scale did not explain the between-study variability in the association of childhood maltreatment with depression course (p=0.611), suggesting that bias due to study quality was unlikely. (The study quality assessment is reported in the data supplement that accompanies the online edition of this article.)

Effect of age at illness onset.

This analysis was based on proxy measures of mean age of the samples. We extracted data on mean age from 15 studies. We did not observe the negative correlation between age of the samples and effect sizes that was expected in the presence of an age-at-onset effect (r=–0.075, 95% CI=–0.541 to 0.392). In addition, meta-regression analysis showed that between-study differences in age of the sample did not explain the between-study variability in the association of childhood maltreatment with depression course (p=0.819), suggesting that confounding by age at onset was unlikely.

Recall bias.

This analysis was based on proxy measures of lifetime history of depression. We extracted data on lifetime prevalence of depression from 14 studies. Meta-regression analysis showed that between-study differences in lifetime prevalence of depression did not explain the between-study variability in the association of childhood maltreatment with depression course (p=0.878), suggesting that recall bias was unlikely.

Clinical Trials

The association between childhood maltreatment and the outcome of treatment with psychological therapy, antidepressant medication, or combined treatment was tested in 10 studies (15 active treatment arms) with a total of 3,098 participants (Table 2) (4554). We identified significant heterogeneity across studies (Q=24.77, df=14, p=0.037) and therefore performed an analysis using a random-effects model. A meta-analysis of these studies revealed that maltreated individuals were more likely than those without a history of childhood maltreatment to show poor treatment outcome (odds ratio=1.43, 95% CI=1.11–1.83) (Figure 3). We performed additional analyses to explore the effect of possible sources of artifact or bias on these results.
TABLE 2. Selected Characteristics of Clinical Trials Investigating the Association Between Childhood Maltreatment and Treatment Outcome of Depression: Improvement, Response, and Remissiona
Authors (Reference)Study NMean Age (Years)% FemaleDepression MeasureMaltreatment MeasureTreatment DescriptionLength of Treatment (Weeks)Outcome DefinitionResults
Sakado et al. (45)604350SCIDPBITricyclic antidepressant16Remission: HAM-D-17 <8Low paternal care associated with lack of remission (odds ratio=1.9, 95% CI=1.7–2.2)
Nemeroff et al. (46)6814365.3SCIDCTSCBASP, nefazodone, combination12Improvement: HAM-D-24 score reductionChildhood abuse associated with poor outcome within the pharmacological treatment arm and good outcome within the psychotherapy treatment arm (trauma-by-treatment interaction F=3.13, df=1, 495, p=0.045)
Barbe et al. (47)10715.875.7K-SADS; BDI ≥ 13CBQCBT, SBFT, NST12–16Remission: free from major depressive disorder diagnosis for ≥2 monthsFamily conflict associated with lack of remission (relative risk=0.95, 95% CI=0.91–0.998)
Enns and Cox (48)17141.864.3Unstructured interviewDMQ, PBIVarious antidepressants and psychological treatments52Response: 50% decrease in BDI scoreRemission: BDI <10Sexual abuse associated with lack of response (χ2=4.32, p=0.038) and lack of remission (χ2=4.38, p=0.036); low parental care or overprotection were unrelated to outcome (p=0.58)
Asarnow et al. (49)28715.969.8CDRS-R ≥40; CGI ≥4; resistance to SSRIsCBQ, clinical interviewMedication switch alone (SSRI or venlafaxine), medication switch plus CBT12Response: CDRS-R score reduction ≥50%Childhood abuse associated with lack of response to CBT but not to pharmacotherapy or combination (abuse-by-treatment interaction β=0.15, p<0.001)
Johnstone et al. (50)1953257Not specifiedPBI, own questionnaireFluoxetine, nortriptyline6Improvement: MADRS score percentage reductionMaternal overprotection was associated with less improvement (odds ratio=0.93, 95% CI=0.89–0.97). Parental care and childhood abuse were unrelated to outcome
Klein et al. (51)80843.655SCID, HAM-D-17 ≥20MOPS, CTQTexas Medication Algorithm12Remission: HAM-D-17 <8Childhood abuse associated with lack of remission (odds ratio=0.52, p<0.01)
Shirk et al. (52)5015.968C-DISC-IVLEQCBT12Remission: free from major depressive disorder diagnosis at the end of treatment Improvement: BDI score reductionChildhood trauma associated with lack of remission (ρ=–0.31 to –0.35, p<0.05)
Lewis et al. (53)42714.654K-SADS-PL, CDRS-R >45PTSD section of K-SADS-PLFluoxetine, CBT, combination, placebo12Improvement: reduction in CDRS-R scoreChildhood trauma associated with poor response to CBT but not with response to fluoxetine or combination treatment (trauma-by-treatment-by-time interaction F=2.02, p<0.05)
Miniati et al. (54)3123973SCIDClinical interviewMedication (citalopram or escitalopram), IPT, combination12Time to remission (Remission: HAM-D-17 <8)Childhood abuse associated with longer time to remission across treatments (hazard ratio=1.68, 95% CI=1.09–2.59)
a
BDI=Beck Depression Inventory; CBASP=Cognitive Behavioral Analysis System of Psychotherapy; CBQ=Conflict Behavior Questionnaire; CBT=cognitive-behavioral therapy; C-DISC-IV=Computerized Diagnostic Interview Schedule for Children; CDRS-R=Children's Depression Rating Scale—Revised; CGI=Clinical Global Impressions scale; CTQ=Childhood Trauma Questionnaire; CTS=Childhood Trauma Scale; DMQ=Developmental Milestones Questionnaire; HAM-D=Hamilton Depression Rating Scale; IPT=interpersonal psychotherapy; K-SADS-PL=Schedule for Affective Disorders and Schizophrenia for School-Age Children–Present and Lifetime Version; LEQ=Life Events Questionnaire; MADRS=Montgomery-Åsberg Depression Rating Scale; MOPS=Measure of Parental Style; NST=nondirective supportive therapy; PBI=Parental Bonding Instrument; SBFT=systemic behavioral family therapy; SCID=Structured Clinical Interview for DSM-IV; SSRI=selective serotonin reuptake inhibitor.
FIGURE 3. Meta-Analysis of Clinical Trials Investigating the Association Between Childhood Maltreatment and Treatment Outcome of Depression (Fixed Effects)a
a Based on the evidence of homogeneous distributions of effect sizes within treatment groups, we present here the results of fixed-effects model meta-analyses for different treatment groups. The overall effect size across treatment groups was estimated with a random-effects model meta-analysis with the following study weights: Nemeroff (psychotherapy): 7.88; Barbe: 2.78; Shirk: 3.49; Lewis (psychotherapy): 2.65; Sakado: 4.36; Nemeroff (pharmacotherapy): 8.03; Asarnow (pharmacotherapy): 7.32; Johnstone: 10.96; Klein: 14.09; Lewis (pharmacotherapy): 2.25; Nemeroff (combined therapy): 8.42; Enns: 7.07; Asarnow (combined therapy): 6.90; Lewis (combined therapy): 3.61; Miniati: 10.18. The red diamonds show the combined effect sizes for studies concerned with psychotherapy, pharmacotherapy, and combined therapy, as well as the overall effect size of the meta-analysis (top to bottom).

Publication bias.

The funnel plot showed symmetrical distribution of the studies and Begg's adjusted rank correlation test was nonsignificant (p=0.553), suggesting that publication bias was unlikely.

Sensitivity analyses.

We performed sensitivity analyses to examine whether the association between childhood maltreatment and treatment outcome was comparable across different treatment modalities (Figure 3). The association between childhood maltreatment and the outcome of psychotherapy was tested in four studies. We did not identify significant heterogeneity across studies (Q=6.03, df=3, p=0.110) and therefore performed an analysis using a fixed-effects model. A meta-analysis of these studies revealed that compared to those without a history of childhood maltreatment, maltreated individuals showed a nonsignificantly higher risk for poor outcome of psychotherapy (odds ratio=1.12, 95% CI=0.68–1.85). The association between childhood maltreatment and the outcome of pharmacological treatment was tested in six studies. We did not identify significant heterogeneity across studies (Q=8.41, df=5, p=0.135) and therefore performed an analysis using a fixed-effects model. A meta-analysis of these studies revealed that maltreated individuals showed a poorer outcome of pharmacological treatment compared to those without a history of childhood maltreatment (odds ratio=1.26, 95% CI=1.01–1.56). The association between childhood maltreatment and the outcome of combined treatment (psychotherapy and antidepressant medications) was tested in five studies. We did not identify significant heterogeneity across studies (Q=4.84, df=4, p=0.304) and therefore performed an analysis using a fixed-effects model. A meta-analysis of these studies revealed that maltreated individuals showed poorer outcome of combined treatment compared to those without a history of childhood maltreatment (odds ratio=1.90, 95% CI=1.40–2.58).

Bias owing to study quality.

Meta-regression analysis showed that between-study differences in quality ratings based on the adapted Jadad scale did not explain the between-study variability in the association of childhood maltreatment with treatment outcome (p=0.383), suggesting that bias due to study quality was unlikely. (The study quality assessment is reported in the online data supplement.)

Age effect.

Meta-regression analysis showed that between-study differences in mean age of the sample did not explain the between-study variability in the association between childhood maltreatment and poor response to antidepressant treatment (p=0.644). Furthermore, a meta-regression analysis showed that classification into pediatric (<18 years) compared with adult samples did not explain the variability in the association between childhood maltreatment and poor response to antidepressant treatment (p=0.498).

Discussion

This meta-analysis addressed the possible developmental origins of heterogeneity in clinically relevant measures of depression such as course of illness and treatment outcome. The epidemiological studies suggested that maltreated individuals were twice as likely as those without a history of childhood maltreatment to develop both recurrent and persistent depressive episodes. Findings from clinical trials were consistent with the epidemiological observations. Compared with depressed individuals without a history of childhood maltreatment, depressed and maltreated individuals appeared to benefit less from treatment (and particularly from combined treatment), thereby incurring greater risk of recurrent and persistent depressive episodes (4).

Limitations

These results should be evaluated in the context of several potential limitations. First, selective publication of studies reporting significant associations between childhood maltreatment and clinically relevant depression measures may influence results. We identified evidence of publication bias in epidemiological studies, but the trim-and-fill procedure suggested that publication bias was unlikely to significantly change the meta-analysis results. In contrast, both graphical and statistical methods suggested that the presence of significant publication bias was unlikely in clinical trials. Second, the results could also be limited to particular outcome measures. However, subgroup analyses appeared to be insensitive to the outcome measures examined. Third, results from epidemiological studies could be limited to clinical or population samples. However, subgroup analyses appeared to be overall insensitive to the sample type examined. Fourth, study quality could have influenced the results. However, differences in study quality could not explain between-study heterogeneity in the association between childhood maltreatment and depression course or treatment outcome. Fifth, the earlier age at onset for depression in maltreated individuals could influence epidemiological study results, leading to spurious findings of greater depression recurrence in maltreated individuals compared with individuals with no history of maltreatment by increasing the amount of time that maltreated individuals spent at risk. However, we could not observe the negative correlation between effect sizes and mean age of the samples that was expected in the presence of age-at-onset effect. In addition, the differences in mean age could not explain between-study heterogeneity in the association between childhood maltreatment and depression course. Sixth, results from epidemiological studies could also be influenced by recall bias owing to between-study differences in lifetime history of depression. However, differences in lifetime history of depression could not explain between-study heterogeneity in the association between childhood maltreatment and depression course. Finally, the available data did not enable us to examine the relative contribution of different maltreatment subtypes or the effect of other potential confounders.

Implications

Despite the potential limitations, the study results have important implications in several areas.

Future research.

Childhood maltreatment may be conceptualized as a developmental risk factor triggering a chain of risks (55) such as subsequent depressive episodes that might progressively potentiate the vulnerability to poor course of illness (56, 57). In order to understand the origins of this chain of risks, studies should explore the cognitive and biological correlates of maltreatment in childhood before the accumulation of multiple depressive episodes (58). Furthermore, it will be important to characterize the gene-environment interplay underlying the effects of childhood maltreatment on depression outcomes (5961). Childhood maltreatment may be conceptualized as an environmental risk factor for poor depression course and a moderator of treatment outcome (62), complementing the emerging genetic markers of vulnerability to recurrent depression (63) and poor treatment response (64, 65).

Clinical care.

Information about a history of childhood maltreatment helps identify individuals who are at high risk of developing a recurrent and persistent subtype of depression and those who will respond poorly to treatment. Because of the lack of placebo-controlled studies, we were unable to test whether depressed and maltreated individuals benefit more or less from treatment (versus placebo) than depressed individuals who were not maltreated. In contrast, we observed that depressed and maltreated individuals have a poorer outcome compared with depressed individuals who were not maltreated (i.e., a poor prognosis) within treatment groups. Clinicians may consider that the routine inquiry about childhood maltreatment is not harmful (66) and could add important prognostic information to their assessment. Clinicians may also consider more intensive and alternative treatment options for depressed individuals with a history of childhood maltreatment. The meta-analytical evidence that maltreated and depressed individuals have a poor response to combined treatment with structured psychological therapy and antidepressant medications indicates that simply combining these two common options is not sufficient. It will be important to explore the response of maltreated and depressed individuals to new treatments targeting the biological vulnerabilities described in this subgroup (7, 60), including elevated inflammation levels (67, 68).

Public health.

Interventions aimed at reducing childhood maltreatment could help prevent the large health and economic burden linked to poor depression course. Childhood years are thought to be a sensitive developmental window for the maturation of emotion regulation (69). Therefore, in the same way that childhood educational interventions have greater returns in human capital formation than interventions at later ages (70), early preventive and therapeutic interventions may be more effective (and cost-effective) in preventing a poor longitudinal course of depression than interventions at later ages, when harmful developmental trajectories have already been established.

Acknowledgments

The authors thank Professor Sir Michael Rutter and Professor George W. Brown for the helpful comments on a previous version of the manuscript.

Footnote

Received Feb. 28, 2011; revision received May 9, 2011; accepted May 26, 2011.

Supplementary Material

File (appi.ajp.2011.11020335.ds001.pdf)

References

1.
Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS: The epidemiology of major depressive disorder. JAMA 2003; 289:3095–3105
2.
Moffitt TE, Caspi A, Taylor A, Kokaua J, Milne BJ, Polanczyk G, Poulton R: How common are common mental disorders? evidence that lifetime prevalence rates are doubled by prospective versus retrospective ascertainment. Psychol Med 2010; 40:899–909
3.
Solomon DA, Keller MB, Leon AC, Mueller TI, Lavori PW, Shea MT, Coryell W, Warshaw M, Turvey C, Maser JD, Endicott J: Multiple recurrences of major depressive disorder. Am J Psychiatry 2000; 157:229–233
4.
Keller MB: Past, present, and future directions for defining optimal treatment outcome in depression. JAMA 2003; 289:3152–3160
5.
Kessler RC: The effects of stressful life events on depression. Annu Rev Psychol 1997; 48:191–214
6.
Beck AT: The evolution of the cognitive model of depression and its neurobiological correlates. Am J Psychiatry 2008; 165:969–977
7.
Danese A, Moffitt TE, Pariante CM, Ambler A, Poulton R, Caspi A: Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch Gen Psychiatry 2008; 65:409–415
8.
Hammen C, Henry R, Daley SE: Depression and sensitization to stressors among young women as a function of childhood adversity. J Consult Clin Psychol 2000; 68:782–787
9.
Danese A, Pariante CM, Caspi A, Taylor A, Poulton R: Childhood maltreatment predicts adult inflammation in a life-course study. Proc Natl Acad Sci USA 2007; 104:1319–1324
10.
Ford DE, Erlinger TP: Depression and c-reactive protein in US adults: data from the third national health and nutrition examination survey. Arch Intern Med 2004; 164:1010–1014
11.
Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H: Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000; 22:370–379
12.
Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissman MM: Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991; 48:851–855
13.
Lipsey MW, Wilson DB: Practical Meta-Analysis. Thousand Oaks, Calif, SAGE Publications, 2000
14.
Hasselblad V, Hedges LV: Meta-analysis of screening and diagnostic tests. Psychol Bull 1995; 117:167–178
15.
Cochran W: The comparison of percentages in matched samples. Biometrika 1950; 37:256–266
16.
Egger M, Smith GD, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629–634
17.
Begg C, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50:1088–1101
18.
Duval S, Tweedie R: A nonparametric “trim and fill” method of accounting for publication bias in meta-analysis. J Am Stat Assoc 2000; 95:89–98
19.
Cohen P, Cohen J: The clinician's illusion. Arch Gen Psychiatry 1984; 41:1178–1182
20.
Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2011. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.
21.
Higgins JPT, Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. 2011. www.cochrane-handbook.org
22.
Paras ML, Murad MH, Chen LP, Goranson EN, Sattler AL, Colbenson KM, Elamin MB, Seime RJ, Prokop LJ, Zirakzadeh A: Sexual abuse and lifetime diagnosis of somatic disorders: a systematic review and meta-analysis. JAMA 2009; 302:550–561
23.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17:1–12
24.
Spatz Widom C, DuMont K, Czaja SJ: A prospective investigation of major depressive disorder and comorbidity in abused and neglected children grown up. Arch Gen Psychiatry 2007; 64:49–56
25.
Uher R, Maier W, Hauser J, Marusic A, Schmael C, Mors O, Henigsberg N, Souery D, Placentino A, Rietschel M, Zobel A, Dmitrzak-Weglarz M, Petrovic A, Jorgensen L, Kalember P, Giovannini C, Barreto M, Elkin A, Landau S, Farmer A, Aitchison KJ, McGuffin P: Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. Br J Psychiatry 2009; 194:252–259
26.
Brewin CR, Andrews B, Gotlib IH: Psychopathology and early experience: a reappraisal of retrospective reports. Psychol Bull 1993; 113:82–98
27.
Hardt J, Rutter M: Validity of adult retrospective reports of adverse childhood experiences: review of the evidence. J Child Psychol Psychiatry 2004; 45:260–273
28.
Brewin CR, Reynolds M, Tata P: Autobiographical memory processes and the course of depression. J Abnorm Psychol 1999; 108:511–517
29.
Mackinger HF, Pachinger MM, Leibetseder MM, Fartacek RR: Autobiographical memories in women remitted from major depression. J Abnorm Psychol 2000; 109:331–334
30.
Kessler RC, Magee WJ: Childhood adversities and adult depression: basic patterns of association in a US national survey. Psychol Med 1993; 23:679–690
31.
Brown G, Moran P: Clinical and psychosocial origins of chronic depressive episodes, I: a community survey. Br J Psychiatry 1994; 165:447–456
32.
Brown G, Harris T, Hepworth C, Robinson R: Clinical and psychosocial origins of chronic depressive episodes, II: a patient enquiry. Br J Psychiatry 1994; 165:457–465
33.
Zlotnick C, Ryan CE, Miller IW, Keitner GI: Childhood abuse and recovery from major depression. Child Abuse Negl 1995; 19:1513–1516
34.
Kessler RC, Davis CG, Kendler KS: Childhood adversity and adult psychiatric disorder in the US National Comorbidity Survey. Psychol Med 1997; 27:1101–1119
35.
Bernet CZ, Stein MB: Relationship of childhood maltreatment to the onset and course of major depression in adulthood. Depress Anxiety 1999; 9:169–174
36.
Hayden EP, Klein DN: Outcome of dysthymic disorder at 5-year follow-up: the effect of familial psychopathology, early adversity, personality, comorbidity, and chronic stress. Am J Psychiatry 2001; 158:1864–1870
37.
Wainwright NWJ, Surtees PG: Childhood adversity, gender and depression over the life-course. J Affect Disord 2002; 72:33–44
38.
Brown GW, Craig TK, Harris TO, Handley RV, Harvey AL: Development of a retrospective interview measure of parental maltreatment using the Childhood Experience of Care and Abuse (CECA) instrument: a life-course study of adult chronic depression, 1. J Affect Disord 2007; 103:205–215
39.
Collishaw S, Pickles A, Messer J, Rutter M, Shearer C, Maughan B: Resilience to adult psychopathology following childhood maltreatment: evidence from a community sample. Child Abuse Negl 2007; 31:211–229
40.
Ritchie K, Jaussent I, Stewart R, Dupuy AM, Courtet P, Ancelin ML, Malafosse A: Association of adverse childhood environment and 5-HTTLPR genotype with late-life depression. J Clin Psychiatry 2009; 70:1281–1288
41.
Wiersma JE, Hovens JG, van Oppen P, Giltay EJ, van Schaik DJ, Beekman AT, Penninx BW: The importance of childhood trauma and childhood life events for chronicity of depression in adults. J Clin Psychiatry 2009; 70:983–989
42.
Angst J, Gamma A, Rössler W, Ajdacic V, Klein D: Childhood adversity and chronicity of mood disorders. Eur Arch Psychiatry Clin Neurosci 2010; 261:21–27
43.
McLaughlin KA, Green JG, Gruber MJ, Sampson NA, Zaslavsky AM, Kessler RC: Childhood adversities and adult psychiatric disorders in the national comorbidity survey replication, II: associations with persistence of DSM-IV disorders. Arch Gen Psychiatry 2010; 67:124–132
44.
Suija K, Aluoja A, Kalda R, Maaroos H: I: factors associated with recurrent depression: a prospective study in family practice. Fam Prac 2011; 28:22–28
45.
Sakado K, Sato T, Uehara T, Sakado M, Someya T: Perceived parenting pattern and response to antidepressants in patients with major depression. J Affect Disord 1999; 52:59–66
46.
Nemeroff CB, Heim CM, Thase ME, Klein DN, Rush AJ, Schatzberg AF, Ninan PT, McCullough JP, Weiss PM, Dunner DL, Rothbaum BO, Kornstein S, Keitner G, Keller MB: Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci USA 2003; 100:14293–14296
47.
Barbe RP, Bridge JA, Birmaher B, Kolko DJ, Brent DA: Lifetime history of sexual abuse, clinical presentation, and outcome in a clinical trial for adolescent depression. J Clin Psychiatry 2004; 65:77–83
48.
Enns MW, Cox BJ: Psychosocial and clinical predictors of symptom persistence vs remission in major depressive disorder. Can J Psychiatry 2005; 50:769–777
49.
Asarnow JR, Emslie G, Clarke G, Wagner KD, Spirito A, Vitiello B, Iyengar S, Shamseddeen W, Ritz L, Birmaher B, Ryan N, Kennard B, Mayes T, DeBar L, McCracken J, Strober M, Suddath R, Leonard H, Porta G, Keller M, Brent D: Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response. J Am Acad Child Adolesc Psychiatry 2009; 48:330–339
50.
Johnstone JM, Luty SE, Carter JD, Mulder RT, Frampton CMA, Joyce PR: Childhood neglect and abuse as predictors of antidepressant response in adult depression. Depress Anxiety 2009; 26:711–717
51.
Klein DN, Arnow BA, Barkin JL, Dowling F, Kocsis JH, Leon AC, Manber R, Rothbaum BO, Trivedi MH, Wisniewski SR: Early adversity in chronic depression: clinical correlates and response to pharmacotherapy. Depress Anxiety 2009; 26:701–710
52.
Shirk SR, Kaplinski H, Gudmundsen G: School-based cognitive-behavioural therapy for adolescent depression. J Emot Behav Disord 2009; 17:106–117
53.
Lewis CC, Simons AD, Nguyen LJ, Murakami JL, Reid MW, Silva SG, March JS: Impact of childhood trauma on treatment outcome in the Treatment for Adolescents With Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2010; 49:132–140
54.
Miniati M, Rucci P, Benvenuti A, Frank E, Buttenfield J, Giorgi G, Cassano GB: Clinical characteristics and treatment outcome of depression in patients with and without a history of emotional and physical abuse. J Psychiatr Res 2010; 44:302–309
55.
Rutter M: Pathways from childhood to adult life. J Child Psychol Psychiatry 1989; 30:23–51
56.
Post RM: Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992; 149:999–1010
57.
Kendler KS, Thornton LM, Gardner CO: Stressful life events and previous episodes in the etiology of major depression in women: an evaluation of the “kindling” hypothesis. Am J Psychiatry 2000; 157:1243–1251
58.
Danese A, Caspi A, Williams B, Ambler A, Sugden K, Mika J, Werts H, Freeman J, Pariante CM, Moffitt TE, Arseneault L: Biological embedding of stress through inflammation processes in childhood. Mol Psychiatry 2011; 16:244–246
59.
Danese A: Genetic opportunities for psychiatric epidemiology: on life stress and depression. Epidemiol Psichiatr Soc 2008; 17:201–210
60.
Uher R: The implications of gene-environment interactions in depression: will cause inform cure? Mol Psychiatry 2008; 13:1070–1078
61.
Uher R: Genes, environments, and individual differences in response to treatment. Harv Rev Psychiatry 2011; 19:109–124
62.
Kraemer HC, Stice E, Kazdin A, Offord D, Kupfer D: How do risk factors work together? mediators, moderators, and independent, overlapping, and proxy risk factors. Am J Psychiatry 2001; 158:848–856
63.
Lewis CM, Ng MY, Butler AW, Cohen-Woods S, Uher R, Pirlo K, Weale ME, Schosser A, Paredes UM, Rivera M, Craddock N, Owen MJ, Jones L, Jones I, Korszun A, Aitchison KJ, Shi J, Quinn JP, Mackenzie A, Vollenweider P, Waeber G, Heath S, Lathrop M, Muglia P, Barnes MR, Whittaker JC, Tozzi F, Holsboer F, Preisig M, Farmer AE, Breen G, Craig IW, McGuffin P: Genome-wide association study of major recurrent depression in the U.K. population. Am J Psychiatry 2010; 167:949–957
64.
Simon GE, Perlis RH: Personalized medicine for depression: can we match patients with treatments? Am J Psychiatry 2010; 167:1445–1455
65.
Uher R, Perroud N, Ng MY, Hauser J, Henigsberg N, Maier W, Mors O, Placentino A, Rietschel M, Souery D, Zagar T, Czerski PM, Jerman B, Larsen ER, Schulze TG, Zobel A, Cohen-Woods S, Pirlo K, Butler AW, Muglia P, Barnes MR, Lathrop M, Farmer A, Breen G, Aitchison KJ, Craig I, Lewis CM, McGuffin P: Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 2010; 167:555–564
66.
Becker-Blease KA, Freyd JJ: Research participants telling the truth about their lives: the ethics of asking and not asking about abuse. Am Psychol 2006; 61:218–226
67.
Miller AH, Maletic V, Raison CL: Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009; 65:732–741
68.
Muller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Moller HJ, Arolt V, Riedel M: The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006; 11:680–684
69.
Shonkoff JP, Boyce WT, McEwen BS: Neuroscience, molecular biology, and the childhood roots of health disparities. JAMA 2009; 301:2252–2259
70.
Heckman JJ: Skill formation and the economics of investing in disadvantaged children. Science 2006; 312:1900–1902

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 141 - 151
PubMed: 22420036

History

Received: 28 February 2011
Revision received: 9 May 2011
Accepted: 26 May 2011
Published online: 1 February 2012
Published in print: February 2012

Authors

Details

Valentina Nanni, M.D.
From King's College London, Institute of Psychiatry, MRC Social, Genetic, and Developmental Psychiatry (SGDP) Research Centre; and King's College London, Institute of Psychiatry, Department of Child and Adolescent Psychiatry in London.
Rudolf Uher, M.U.Dr., Ph.D.
From King's College London, Institute of Psychiatry, MRC Social, Genetic, and Developmental Psychiatry (SGDP) Research Centre; and King's College London, Institute of Psychiatry, Department of Child and Adolescent Psychiatry in London.
Andrea Danese, M.D., Ph.D.
From King's College London, Institute of Psychiatry, MRC Social, Genetic, and Developmental Psychiatry (SGDP) Research Centre; and King's College London, Institute of Psychiatry, Department of Child and Adolescent Psychiatry in London.

Notes

Address correspondence to Dr. Danese ([email protected]).

Funding Information

The authors report no financial relationships with commercial interests. Dr. Nanni is supported by a fellowship for higher training in Psychiatry from the Italian Ministry of University and Scientific Research. Dr. Uher is supported by a grant from the European Commission (Grant Agreement #115008). Dr. Danese is supported by a NARSAD Young Investigator Award.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share